A Mixed Start for Immunotherapy in Childhood Cancers A Mixed Start for Immunotherapy in Childhood Cancers

KEYNOTE-051 establishes a recommended pediatric dose for pembrolizumab and shows encouraging antitumor activity in one cancer type, but it was less effective in multiple other malignancies.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news